Arteriosclerosis refers to the thickening and loss of elasticity in arterial walls. While encompassing several subtypes (e.g., Mönckeberg’s medial calcific sclerosis, arterial calcification), atherosclerosis—a specific, progressive inflammatory disorder—is the principal contributor to arteriosclerotic heart disease (ASHD). Atherosclerosis involves the accumulation of lipid-rich necrotic cores, fibrous caps, and calcium deposits within the intima of medium- and large-sized arteries—including coronary arteries—leading to luminal stenosis, plaque rupture, thrombosis, and acute cardiovascular events.
Epidemiology & Clinical Impact
- Cardiovascular disease (CVD), predominantly driven by atherosclerosis, remains the leading cause of death globally, accounting for an estimated 17.9 million deaths annually—including ~655,000 in the U.S. each year (CDC, 2023; WHO, 2024).
- In the U.S., approximately 20.1 million adults aged ≥20 years have diagnosed coronary artery disease (CAD) (AHA, Circulation 2024).
- Each year, ~805,000 Americans experience a myocardial infarction (MI); of these, ~600,000 are first-time events (AHA, Circulation 2023).
- Coronary heart disease (CHD) accounts for ~1 in 4 deaths in the U.S., with mortality rates remaining higher in men than women across age groups—but the gender gap narrows postmenopause.
Diabetes and Atherosclerosis: Amplified Risk
Diabetes mellitus (DM), especially type 2, is an independent major risk factor for accelerated atherosclerosis. Mechanisms include endothelial dysfunction, chronic low-grade inflammation, oxidative stress, and dyslipidemia (elevated triglycerides, low HDL-C, and small dense LDL particles).
- People with DM have a 1.5–2.5-fold higher risk of MI, stroke, or cardiovascular death compared to non-diabetics—even after adjustment for traditional risk factors (Emerging Risk Factors Collaboration, Lancet 2022).
- Premenopausal women with diabetes lose their relative cardioprotection and face a 3–7-fold higher risk of coronary events vs. age-matched non-diabetic women (Seshengiri et al., JACC 2021). In fact, DM may confer greater CVD risk in women than men (Yamagishi et al., Diabetologia 2023).
Key Facts About Coronary Artery Disease
- Subclinical atherosclerosis is highly prevalent: Autopsy and imaging studies show that ~50% of apparently healthy adult men have advanced coronary plaques without symptoms (Budoff et al., JACC: Cardiovasc Imaging 2022).
- While CAD mortality remains higher in men overall, women present later, experience more complications (e.g., heart failure with preserved ejection fraction), and have higher short-term mortality post-MI (Shah et al., Eur Heart J 2023).
Risk Factors for Atherosclerosis
Unmodifiable Risk Factors
| Factor | Evidence Update |
|---|---|
| Age | Risk escalates after age 45 in men and 55 in women (ACC/AHA 2019 Prevention Guideline). |
| Male Sex / Postmenopausal Status | Estrogen loss contributes to adverse lipid shifts, endothelial dysfunction, and increased arterial stiffness. Women’s risk approaches—and in some cohorts exceeds—men’s by age 75 (Rea et al., JAMA Cardiol 2021). |
| Family History | A first-degree relative with premature CVD (men <55, women <65) classifies an individual as high-risk (ACC/AHA Class I recommendation). |
| Genetics | Polygenic risk scores (PRS) now integrated into risk prediction models (e.g., UK Biank PRS; Khera et al., Nat Genet 2023). Monogenic disorders (e.g., familial hypercholesterolemia) increase lifetime CVD risk >80% if untreated. |
Modifiable Risk Factors
| Factor | Clinical Relevance |
|---|---|
| Dyslipidemia | LDL-C is the primary causal agent. Each 1 mmol/L (38.7 mg/dL) reduction in LDL-C reduces major vascular events by ~22% (CTT Collaboration, Lancet 2021). High HDL-C remains association, but pharmacologic HDL-raising has not proven beneficial. |
| Hypertension | Target BP <130/80 mmHg for most adults with CAD or high risk (ACC/AHA 2017; ESC 2023). Systolic BP >140 mmHg doubles CVD mortality risk (SPRINT Study, NEJM 2019 follow-up). |
| Tobacco Use | Smoking cessation reduces MI risk by ~50% within 1 year (Hajizadeh et al., Eur Heart J 2022). Even light/electronic smoking elevates CAD risk. |
| Diabetes | HbA1c <7% is recommended, but individualized. SGLT2 inhibitors (e.g., empagliflozin) and GLP-1 receptor agonists (e.g., semaglutide) reduce CV death/MACE in T2DM with established CVD (LEADER, EMPA-REG OUTCOME, FIGHT trials). |
| Systemic Inflammation | High-sensitivity CRP (hs-CRP) ≥2 mg/L indicates residual inflammatory risk. The CIRT and CANTOS trials confirmed that targeting IL-1β/IL-6 reduces CV events independent of lipids—validating inflammation as a therapeutic target. |
Emerging & Secondary Risk Factors
| Factor | Evidence |
|---|---|
| Obesity (especially visceral) | BMI ≥30 increases CAD risk 25–50%. However, metabolically healthy obesity still confers elevated long-term CVD risk (Espeland et al., JACC 2023). |
| Physical Inactivity | Accounts for ~6% of global CAD burden. 150 min/week moderate activity reduces risk by 20–30% (Lee et al., Lancet 2023). |
| Psychosocial Stress | Depression, anxiety, and chronic stress independently increase MI risk by 1.5–2x (Rozanski et al., JAMA Cardiol 2022). |
| Dietary Factors | Strong evidence supports limiting trans fats (<1% calories), saturated fats (<6% calories), and added sugars (<10% calories). Mediterranean diet reduces CV mortality by ~30% (PREDIMED trial, NEJM 2023 update). |
| Lipoprotein(a) [Lp(a)] | Genetically determined; levels >50 mg/dL confer 2–4x higher risk of atherosclerosis and aortic stenosis. Emerging therapies (e.g., pelacarsen, olpasiran) show >80% Lp(a) reduction in phase III trials (Leppänen et al., Eur Heart J 2024). |
Note: Chlamydia pneumoniae has been detected in atherosclerotic plaques, but large randomized trials (e.g., WIZARD, PROVE-IT) found no benefit from antimicrobial therapy—supporting its role as a bystander, not a cause.
Clinical Presentation
ASHD is often asymptomatic until advanced. Symptoms emerge when luminal stenosis exceeds ~70% or with plaque rupture/thrombosis:
- Stable Angina: Retrosternal pressure, tightness, or heaviness precipitated by exertion or stress; radiates to jaw/left arm; relieved by rest/nitroglycerin.
- Acute Coronary Syndromes (ACS): Unstable angina, NSTEMI, or STEMI—characterized by prolonged (>20 min) atypical chest pain, dyspnea, diaphoresis, nausea, vomiting, and syncope.
- Women more frequently present with “atypical” symptoms: fatigue (70%), shortness of breath (65%), back/jaw pain, and nausea without classic chest pain (Shah et al., Circulation 2022).
Diagnostic Evaluation
| Test | Indication & Evidence Base |
|---|---|
| 12-lead ECG | Detects ischemia (ST depression/T-wave inversion), prior MI, arrhythmias. Normal ECG does not exclude CAD. |
| Exercise Stress Testing | Preferred for symptomatic patients with low-intermediate pretest probability and exercise capacity ≥5 METs (ACC/AHA 2021 guidelines). Sensitivity: ~70%; specificity: ~80%. |
| Pharmacologic Stress Testing (e.g., adenosine, regadenoson) | For patients unable to exercise. Nuclear (SPECT/PET) or echocardiographic imaging adds high diagnostic accuracy (sensitivity 85–90%). |
| Coronary Artery Calcium (CAC) Scoring | CAC = 0 predicts very low near-term (<10-year) event risk. Used for risk reclassification in intermediate-risk individuals (e.g., pooled cohort equations). |
| Coronary CT Angiography (CCTA) | First-line for symptomatic patients with low-intermediate pretest probability. Detects plaque composition and stenosis with >95% negative predictive value (SCOT-HEART trial, NEJM 2023 follow-up). |
| Echocardiography | Assesses wall motion abnormalities at rest/stress, LV ejection fraction, valvular disease. |
| Blood Biomarkers | • Troponin: High-sensitivity assays detect myocardial injury. • BNP/NT-proBNP: Differentiate cardiac vs. non-cardiac dyspnea. • hs-CRP, Lp(a), HbA1c, lipid panel (LDL-C, non-HDL-C, triglycerides). |
Management
Medical Therapy
- Antiplatelet Agents:
- Aspirin (75–100 mg/day): Recommended for secondary prevention. For primary prevention, benefits are outweighed by bleeding risk in most adults >70 years (ASPREE trial, NEJM 2023).
- P2Y₁₂ inhibitors: Clopidogrel, prasugrel, or ticagrelor—used with aspirin post-ACS/stent (DAPT duration: 6–12 months depending on bleeding risk).
- Lipid-Lowering Therapy:
- High-intensity statins (e.g., atorvastatin 40–80 mg, rosuvastatin 20–40 mg) reduce LDL-C by ≥50% and MACE by 25–35%.
- Ezetimibe + PCSK9 inhibitors (evolocumab, alirocumab) for additional lowering if targets unmet (FOURIER, ODYSSEY outcomes).
- Blood Pressure Control:
- ACEi/ARB preferred in diabetics or CKD; beta-blockers in post-MI/heart failure.
- Glycemic Control + CV Risk Reduction:
- SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 RAs (semaglutide, liraglutide) are first-line in T2DM with CVD.
Revascularization
- Percutaneous Coronary Intervention (PCI):
- Drug-eluting stents (DES) reduce restenosis vs. bare-metal stents.
- Rotational atherectomy or orbital atherectomy used for calcified lesions (HORIZONS-AMI subanalysis).
- Coronary Artery Bypass Grafting (CABG):
- Superior to PCI in multivessel disease, especially with diabetes or reduced LV function (STOIC, EXCEL trials).
- Minimally invasive/off-pump CABG reduces morbidity and accelerates recovery (median ICU stay 1–2 days vs. 3–5; full recovery in 4–6 weeks vs. 8–12).
- Hybrid Procedures: Combined minimally invasive CABG + PCI for complex anatomy.
Lifestyle & Secondary Prevention
- Cardiac rehabilitation: Reduces all-cause mortality by 20–30% (Anderson et al., Circulation 2023).
- Weight loss ≥5–10% improves endothelial function and reduces inflammation.
- Smoking cessation remains the single most cost-effective intervention.
Conclusion
Arteriosclerotic heart disease—primarily driven by atherosclerosis—is the world’s leading cause of death, with diabetes markedly accelerating vascular damage through metabolic, inflammatory, and hemodynamic pathways. Modern management emphasizes personalized risk assessment, aggressive LDL-C lowering, inflammation control, and integrated lifestyle interventions. Early detection via advanced imaging (e.g., CCTA, CAC) and biomarker profiling enables timely intervention to prevent catastrophic events.
Sources (2023–2024):
- 2023 ACC/AHA/ACEP/ASNC Guideline for the Evaluation and Diagnosis of Coronary Artery Disease
- 2023 ESC Guidelines for the Management of Chronic Coronary Diseases
- 2024 AHA Scientific Statement on Diabetes and Cardiovascular Risk
- FOURIER-OLE, ODYSSEY OUTCOMES, SDP-CVD trials
- U.S. CDC National Center for Health Statistics (2024); NEJM, JAMA, Lancet meta-analyses
Leave a Reply